Rosetta Inpharmatics: Translating Genes into Profits?

Merck's acquisition of the genomics pioneer may give the No. 2 pharmaceutical company a huge advantage in developing new drugs

By David Shook

To continue reading this article you must be a Bloomberg Professional Service Subscriber.